편두통 치료의 최신 지견

키워드

참고문헌 (48)

1. Headache classification committee of the International Headache Society(IHS), "The international classification of headache disorders, 3rd edition", Cephalalgia, 38, pp.1~211 (2018)
2. 김병건, "Prevalence and Impact of Migraine and Tension-Type Headache in Korea", Journal of Clinical Neurology, 8(3), pp.204~211 (2012), 대한신경과학회[DOI]
3. Kim BK, "Prevalence, clinical characteristics and disability of migraine and probable migraine : a nationwide population-based survey in Korea", Cephalalgia, 33, pp.1106~1116 (2013)
4. "Global health estimates 2015: disease burden by cause, age, sex, by country and by region, 2000-2015" (2016)[URL]
5. GBD 2015 Neurological Disorders Collaborator Group, "Global, regional, and national burden of neurological disorders during 1990-2015 : a systematic analysis for the Global Burden of Disease Study 2015", Lancet Neurol, 16, pp.877~897 (2017)
6. Steiner TJ, "Migraine is first cause of disability in under 50s : will health politicians now take notice", J Headache Pain, 19, pp.17~ (2018)
7. American Headache Society, "The American Headache Society position statement on integrating new migraine treatments into clinical practice", Headache, 59, pp.1~18 (2019)
8. Marmura MJ, "The acute treatment of migraine in adults : the American Headache Society evidence assessment of migraine pharmacotherapies", Headache, 55, pp.3~20 (2015)
9. Millson DS, "Migraine pharmacotherapy with oral triptans : a rational approach to clinical management", Expert Opin Pharmacother, 1, pp.391~404 (2000)
10. Brandes JL, "Sumatriptan-naproxen for acute treatment of migraine : a randomized trial", JAMA, 297, pp.1443~1454 (2007)
11. Tullo V, "Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg)with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study", Cephalalgia, 34, pp.434~445 (2014)
12. Dodick DW, "Ubrogepant for the Treatment of Migraine", N Engl J Med, 381, pp.2230~2241 (2019)
13. Negro A, "Gepants for the treatment of migraine", Expert Opin Investig Drugs, 28, pp.555~567 (2019)
14. Lipton RB, "Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine", N Engl J Med, 381, pp.142~149 (2019)
15. Raffaelli B, "The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine", Expert Opin Pharmacother, 18, pp.1409~1415 (2017)
16. Lipton RB, "Migraine prevalence, disease burden, and the need for preventive therapy", Neurology, 68, pp.343~349 (2007)
17. Stewart WF, "Development and testing of the Migraine Disability Assessment(MIDAS)questionnaire to assess headache-related disability", Neurology, 56(Suppl 1), pp.S20~S28 (2001)
18. Silberstein SD, "Evidence-based guideline update : pharmacologic treatment for episodic migraine prevention in adults : report of the quality standards subcommittee of the American Academy of Neurology and the American Headache Society", Neurology, 78, pp.1337~1345 (2012)
19. Starling AJ, "A narrative review of evidence-based preventive options for chronic migraine", Curr Pain Headache Rep, 19, pp.49~ (2015)
20. Silberstein SD, "Pharmacological approaches to managing migraine and associated comorbidities-clinical considerations for monotherapy vs polytherapy", Headache, 47, pp.585~599 (2007)
21. Song TJ, "Anxiety and depression in probable migraine : a population-based study", Cephalalgia, 37, pp.845~854 (2017)
22. Hepp Z, "Adherence to oral migraine-preventive medications among patients with chronic migraine", Cephalalgia, 35, pp.478~488 (2015)
23. Tassorelli C, "Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults", Cephalalgia, 38, pp.815~832 (2018)
24. Cho SJ, "Outcome of chronic daily headache or chronic migraine", Curr Pain Headache Rep, 20, pp.2~ (2016)
25. Aurora SK, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial", Cephalalgia, 30, pp.793~803 (2010)
26. Diener HC, "OnabotulinumtoxinA for treatment of chronic migraine : results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial", Cephalalgia, 30, pp.804~814 (2010)
27. Goadsby PJ, "A controlled trial of erenumab for episodic migraine", N Engl J Med, 377, pp.2123~2132 (2017)
28. Dodick DW, "Effect of fremanezumab compared with placebo for prevention of episodic migraine : a randomized clinical trial", JAMA, 319, pp.1999~2008 (2018)
29. Stauffer VL, "Evaluation of galcanezumab for the prevention of episodic migraine : the EVOLVE-1 randomized clinical trial", JAMA Neurol, 75, pp.1080~1088 (2018)
30. Skljarevski V, "Efficacy and safety of galcanezumab for the prevention of episodic migraine : results of the EVOLVE-2 phase 3 randomized controlled clinical trial", Cephalalgia, 38, pp.1442~1454 (2018)
31. Ashina M, "Eptinezumab in episodic migraine : a randomized, double-blind, placebo-controlled study(PROMISE-1)", Cephalalgia, 40, pp.241~254 (2020)
32. Tepper S, "Safety and efficacy of erenumab for preventive treatment of chronic migraine : a randomised, double-blind, placebo-controlled phase 2 trial", Lancet Neurol, 16, pp.425~434 (2017)
33. Silberstein SD, "Fremanezumab for the preventive treatment of chronic migraine", N Engl J Med, 377, pp.2113~2122 (2017)
34. Detke HC, "Galcanezumab in chronic migraine : the randomized, double-blind, placebo-controlled REGAIN study", Neurology, 91, pp.2211~2221 (2018)
35. "FDA approves Lundbeck’s Vyepti™(eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine" (2020)[URL]
36. "Drugs@FDA: FDA approved drug products. Methysergide maleate" (2001)[URL]
37. Reuter U, "Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful : a randomised, double-blind, placebo-controlled, phase 3b study", Lancet, 392, pp.2280~2287 (2018)
38. Ferrari MD, "Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes(FOCUS) : a randomised, double-blind, placebo-controlled, phase 3b trial", Lancet, 394, pp.1030~1040 (2019)
39. Mulleners W, "A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine : results from the 3-month double-blind treatment phase of the CONQUER study", J Neurol Sci, 405(Suppl), pp.128~ (2019)
40. Starling AJ, "A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention(ESPOUSE Study)", Cephalalgia, 38, pp.1038~1048 (2018)
41. Chou DE, "External trigeminal nerve stimulation for the acute treatment of migraine : open-label trial on safety and efficacy", Neuromodulation, 20, pp.678~683 (2017)
42. Nestoriuc Y, "Biofeedback treatment for headache disorders : a comprehensive efficacy review", Appl Psychophysiol Biofeedback, 33, pp.125~140 (2008)
43. Andrasik F, "Biofeedback in headache : an overview of approaches and evidence", Cleve Clin J Med, 77(Suppl 3), pp.S72~S76 (2010)
44. Harris P, "Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults", Br J Pain, 9, pp.213~224 (2015)
45. Holroyd KA, "Psychosocial interventions in the management of recurrent headache disorders. 1: overview and effectiveness", Behav Med, 20, pp.53~63 (1994)
46. Cousins S, "A pilot study of cognitive behavioural therapy and relaxation for migraine headache : a randomised controlled trial", J Neurol, 262, pp.2764~2772 (2015)
47. Cho SJ, "Treatment update of chronic migraine", Curr Pain Headache Rep, 21, pp.26~ (2017)
48. Holroyd KA, "Effect of preventive(beta blocker)treatment, behavioral migraine management, or their combination on outcomes of optimized acute treatment in frequent migraine : randomized controlled trial", BMJ, 341, pp.c4871~ (2010)

관련 논문AI추천